Legrand V
Service de Cardiologie, CHU de Liège, Belgique.
Rev Med Liege. 2009 May-Jun;64(5-6):310-2.
Clinical efficacy of antiplatelet agents administration to reduce ischemic complications has supported the concept of atherothrombosis and plaque rupture. Specifically, administration of monoclonal antibody against platelet membrane receptor glycoprotein IIb/IIa was shown to be highly effective whenever percutaneous intervention is performed in the setting of unstable coronary syndrome. The in-hospital use of glycoprotein IIb/IIIa is unanimously recommended in these situations.
使用抗血小板药物降低缺血性并发症的临床疗效支持了动脉粥样硬化血栓形成和斑块破裂的概念。具体而言，在不稳定型冠状动脉综合征患者进行经皮介入治疗时，给予抗血小板膜受体糖蛋白IIb/IIa单克隆抗体显示出高效性。在这些情况下，一致推荐在院内使用糖蛋白IIb/IIIa。
